Alloy Ventures traces its roots back to 1977. Its rich history of early-stage venture investing over several economic cycles has produced industry-leading companies such as Amgen, AMCC, Applied Biosystems, Aspect Communications, CV Therapeutics, Favrille, IDEC Pharmaceuticals, Nuance, Octel, PMC-Sierra, Red Brick Systems, Remedy and Verity to name a few. The partners of Alloy Ventures have helped start and cultivate more than 200 successful companies in the fields of information technology and life sciences. Alloy Ventures has over $1 billion under management.
ARCH Venture Partners is one of the largest seed venture capital firms, and operates nationally in the U.S. with offices in Albuquerque, Austin, Chicago, and Seattle. AVP manages over $1 billion in capital. Founded in the mid-1980s, ARCH has been part of the founding investment round of over 100 companies, specializing in building companies around research emanating from major academic research universities, national laboratories, and corporate research labs in the U.S.
Avalon Ventures is a San Diego-based venture capital fund focusing on seed and early stage companies in life sciences, wireless communications and Web 3.0 digital media, primarily in California and the Northeast. Our current Fund, Avalon VIII, L.P. is $150 million. Avalon Ventures is one of the longest-standing venture capital firms in San Diego, investing in life sciences and information technology opportunities locally and around the country since 1983 through eight Avalon Ventures funds.
(www.TinyTechVC.com) is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 19 initial private equity investments have been in tiny-technology enabled companies. The Company has 17,248,845 common shares outstanding.
Headland Ventures is a venture partnership singularly focused on building successful companies from the ground up. Headland concentrates on the connectivity provided by the next generation communications network and the companies defining its direction.
In-Q-Tel is a private, independent, not-for-profit venture group funded by the CIA. Launched in 1999, In-Q-Tel's mission is to identify and invest in companies developing cutting-edge information technologies that serve United States national security interests. Working from an evolving strategic blueprint that defines the CIAs critical information technology needs, In-Q-Tel engages with entrepreneurs, established companies, researchers and venture capitalists to deliver technologies that pay out in superior intelligence capabilities for the CIA and the larger Intelligence Community.
Lux Capital is a research-driven investment firm focused on building businesses of lasting value. Lux uncovers and creates market-leading companies in the physical and life sciences by leveraging our vast network, proprietary business intelligence and unique access.
Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with combined committed capital of more than $800 million. Oxford Bioscience Partners has achieved considerable success and above average returns in the bioscience field over the past 20 years through investments in more than 100 companies worldwide.